How to Achieve a Good Phage Therapy Clinical Trial?
Modern and well-conducted clinical trials in phage therapy are counted on the fingers of a single hand. Needless to say, individual case treatments are numerous, especially in Eastern European countries like Russia, Georgia, or Poland. But most of the scientific evidence trials are missing or considered useless because of the current, pragmatic, and daily medicinal practice of phage therapy in these countries. However, in Western countries, phage therapy disappeared from pharmacopoeias for most than three decades and bacteriophages are unknown to the young generations of clinicians. The clinical knowledge data base needs to be rebuilt according to the most recent evaluation criteria.
This book chapter aims at providing supportive clinical and patient case data, but especially to provide practical recommendations for performing a phage therapy trial in line with Good Clinical Practices (GCP). A special focus is given on one-size-fits-all clinical trials in comparison to the recent regulatory evolution leading to personalized phage therapy treatments after preliminary diagnostic (phagogram). In addition, the authors are trying to open perspectives to speed up the recruitment process and reduce the length of phage therapy trials, by taking an example on the evaluation of personalized treatments in immuno-oncology.
The choice of primary endpoint tailored to the self-propagation properties of bacteriophages is also studied, in the context of Minimum Inhibition Concentration (MIC) standard used for antibiotic evaluation and often recommended for other anti-infective products, even if inappropriate.
- Abedon S (2011) Phage therapy pharmacology: calculating phage dosing. Adv Appl Microbiol 77:1–40. https://doi.org/10.1016/B978-0-12-387044-5.00001-7 CrossRefPubMedGoogle Scholar
- Babalova EG, Katsitadze KT, Sakvarelidze LA, et al (1968) [Preventive value of dried dysentery bacteriophage]. Zh Mikrobiol Epidemiol Immunobiol 45:143–145Google Scholar
- Ferry T, Boucher F, Fevre C et al (2018) Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages. J Antimicrob Chemother 73:2901–2903. https://doi.org/10.1093/jac/dky263 CrossRefPubMedGoogle Scholar
- Golan T, Milella M, Ackerstein A, Berger R (2017) The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). J Exp Clin Cancer Res 36:192. https://doi.org/10.1186/s13046-017-0668-0 CrossRefPubMedPubMedCentralGoogle Scholar
- ICMJE | Recommendations | Clinical Trials. http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. Accessed 30 Mar 2019
- Jault P, Leclerc T, Jennes S et al (2019) Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 19:35–45. https://doi.org/10.1016/S1473-3099(18)30482-1 CrossRefGoogle Scholar
- Jennes S, Merabishvili M, Soentjens P et al (2017) Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report. Crit Care 21. https://doi.org/10.1186/s13054-017-1709-y
- Międzybrodzki R, Borysowski J, Weber-Dąbrowska B et al (2012) Clinical aspects of phage therapy. Adv Virus Res 83:73–121. https://doi.org/10.1016/B978-0-12-394438-2.00003-7 CrossRefPubMedPubMedCentralGoogle Scholar
- Morozova VV, Vlassov VV, Tikunova NV (2018) Applications of bacteriophages in the treatment of localized infections in humans. Front Microbiol 9. https://doi.org/10.3389/fmicb.2018.01696
- Schooley RT, Biswas B, Gill JJ et al (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61:e00954–e00917. https://doi.org/10.1128/AAC.00954-17 CrossRefPubMedPubMedCentralGoogle Scholar